fbpx

Year

2016
Complete bioavailability after subcutaneous administration of ceftriaxone — Equivalent antimicrobial coverage (time over MIC) to standard intravenous administration FOR IMMEDIATE RELEASE: Lexington, MA., October 31, 2016 /PRNewswire/ — scPharmaceuticals, Inc., a privately held biopharmaceutical company developing transformative pharmaceutical products for subcutaneous delivery, announced today the presentation of study results at IDWeek 2016 in New Orleans, Louisiana. The...
Once again this year, Lundbeckfonden is awarding talent prizes to four talented young scientists under the age of 30. All four have made remarkable and promising contributions to research at a very early stage of their careers. “Supporting and contributing to the development of the careers of scientists is one of Lundbeckfonden’s cornerstones. These young...
Dr. Håkan Björklund of Tellacq AB will be joining the BONESUPPORT Board as Chairman in conjunction with the fund raising, subject to shareholder approval. Dr. Björklund has a long and successful track record in the healthcare industry, including as the former CEO of Nycomed, which he grew from a small Scandinavian company into a global...
Each year, Lundbeckfonden allocates around 10% of its grants to fellowships for some of the most talented scientists at Danish universities and research institutions. Consequently, they constitute a significant proportion of the foundation’s contribution to biomedical sciences research in Denmark. This year is no exception. Five new Lundbeckfonden fellows were officially presented with their research...
Alexander Zelikin is receiving the prize for his impressive work to design materials that deliver drugs to the part of the body that needs them and ensure that they are activated and take effect in that precise location. This year’s prize winner is a world-leader in the development of medical polymers and biomedical design. In...
The recently initiated Phase II study is the first clinical investigation of SNF472 in patients with newly diagnosed calciphylaxis. Designed as an open-label investigation, eligible patients will be treated over three months to assess the effect of SNF472 on wound healing and pain. The trial is led by Prof Vincent Brandenburg, University Hospital RWTH Aachen,...
Prof. Dr. Thorsten Marquardt, Head of Metabolic Disorders, University Hospital Münster, and the study’s lead principal investigator in Germany, noted: “The current clinical program with VTS-270 is aimed at treating the neurological disease that is the primary cause of mortality in children with NPC. Based on preclinical data suggesting that HPbCDs may not cross the...
Dr. Domenic Sica, Professor of Medicine and Pharmacology at the Medical College of Virginia Commonwealth University in Richmond and immediate past president of the American Society of Hypertension, presented the study titled “Pharmacokinetic and Pharmacodynamic Response after Subcutaneous Administration of a Novel Furosemide Formulation.” The cross-over study in patients with heart failure compared subcutaneous administration...
Novel Buffered Subcutaneous Furosemide Combines Lower Cost and Therapeutic Benefit for Patients with Heart Failure Nothing else matters if you don’t get the basics right. The route of drug administration can have dramatically different pharmacodynamic profiles, with most of the drug quickly wasted if the optimal route is not used, according to Domenic Sica, MD,...
In addition, PsiOxus has also announced a reorganization of the executive team with Dr Brian Champion, formerly SVP Research and Development, becoming Chief Scientific Officer whilst Dr Kerry Fisher, the former Chief Scientific Officer, will become Founding Scientist and a member of the Scientific Advisory Board. Priya Mande will take on additional new responsibilities in her role as...
1 2 3 4 8

Nyheder

New test exposes dangerous moles
14. February 2020
Asthma is programmed early in life
7. February 2020
A female dog may well be the answer
24. January 2020

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge